Invitae Claws At $50m, Selling Reproductive Health Assets

Natera has pounced on the opportunity to purchase Invitae’s reproductive health assets at a bargain price, simultaneously quashing any potential ongoing royalty payments between the two.

• Source: Shutterstock

After posting consistently poor financial results, genetic-test developerInvitae has implemented its most drastic cost-saving measure to date, selling off its reproductive health business to Natera.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight